Ignite Creation Date:
2024-05-06 @ 8:29 PM
Last Modification Date:
2024-10-26 @ 3:28 PM
Study NCT ID:
NCT06391944
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-04-30
First Post:
2024-04-26
Brief Title:
JMT101 Combined With Osimertinib in Patients With Stage Ⅲb-Ⅳ Non-small Cell Lung Cancer NSCLC Characterized by Epithermal Growth Factor Receptor EGFR Common Mutations
Sponsor:
Shanghai JMT-Bio Inc
Organization:
Shanghai JMT-Bio Inc
Organization Data
Organization:
Shanghai JMT-Bio Inc
Class:
INDUSTRY
Study ID:
JMT101-CSP-005
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Shanghai JMT-Bio Inc
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None